Evidence map›Paper›PMID 38236844›Full record

ArticlePLOS global public health2024

Perceptions toward Ebola vaccination and correlates of vaccine uptake among high-risk community members in North Kivu, Democratic Republic of the Congo.

Shiromi M Perera, Stephanie Chow Garbern, Eta Ngole Mbong, Monica K Fleming, Rigobert Fraterne Muhayangabo, Arsene Baleke Ombeni, Shibani Kulkarni, Dieula Delissaint Tchoualeu, Ruth Kallay, Elizabeth Song and 13 more

Open access · goldAbstract read
In one paragraph

Article in PLOS global public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 6 institutions in 2 countries.

Shiromi M PereraInternational Medical Corps, Washington, District of Columbia, United States of America.ORCID https://orcid.org/0000-0002-9799-3568
Stephanie Chow GarbernDepartment of Emergency Medicine, Brown University, Providence, Rhode Island, United States of America.
Eta Ngole MbongInternational Medical Corps, Goma, Democratic Republic of the Congo.ORCID https://orcid.org/0000-0001-8911-0684
Monica K FlemingGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Rigobert Fraterne MuhayangaboInternational Medical Corps, Goma, Democratic Republic of the Congo.
Arsene Baleke OmbeniInternational Medical Corps, Goma, Democratic Republic of the Congo.
Shibani KulkarniGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Dieula Delissaint TchoualeuGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.ORCID https://orcid.org/0000-0003-0553-3685
Ruth KallayGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.ORCID https://orcid.org/0000-0003-0781-1343
Elizabeth SongBrown University, Providence, Rhode Island, United States of America.ORCID https://orcid.org/0009-0003-2146-260X
Jasmine PowellBrown University, Providence, Rhode Island, United States of America.
Monique GaineyRhode Island Hospital, Providence, Rhode Island, United States of America.
Bailey GlennGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Ruffin Mitume MutumwaInternational Medical Corps, Goma, Democratic Republic of the Congo.
Stephane Hans Bateyi MustafaExpanded Programme on Immunization, Goma, Democratic Republic of the Congo.
Giulia Earle-RichardsonNational Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Rena FukunagaDivision of Global HIV and TB, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Neetu AbadGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Gnakub Norbert SokeDivision of Global Health Protection, Centers for Disease Control and Prevention, Kinshasa, Democratic Republic of the Congo.
Dimitri PrybylskiGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
David L FitterGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Adam C LevineDepartment of Emergency Medicine, Brown University, Providence, Rhode Island, United States of America.ORCID https://orcid.org/0000-0003-3982-3824
Reena H DoshiGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Centers for Disease Control and Prevention · USBrown University · USInternational Medical Corps · USMinistry of Public Health · CDObservatoire Volcanologique de Goma · CDProvidence College · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tenth Ebola Virus Disease (EVD) outbreak (2018-2020, North Kivu, Ituri, South Kivu) in the Democratic Republic of the Congo (DRC) was the second-largest EVD outbreak in history. During this outbreak, Ebola vaccination was an integral part of the EVD response. We evaluated community perceptions toward Ebola vaccination and identified correlates of Ebola vaccine uptake among high-risk community members in North Kivu, DRC. In March 2021, a cross-sectional survey among adults was implemented in three health zones. We employed a sampling approach mimicking ring vaccination, targeting EVD survivors, their household members, and their neighbors. Outbreak experiences and perceptions toward the Ebola vaccine were assessed, and modified Poisson regression was used to identify correlates of Ebola vaccine uptake among those offered vaccination. Among the 631 individuals surveyed, most (90.2%) reported a high perceived risk of EVD and 71.6% believed that the vaccine could reduce EVD severity; however, 63.7% believed the vaccine had serious side effects. Among the 474 individuals who had been offered vaccination, 397 (83.8%) received the vaccine, 180 (45.3%) of those vaccinated received the vaccine after two or more offers. Correlates positively associated with vaccine uptake included having heard positive information about the vaccine (RR 1.30, 95% CI 1.06-1.60), the belief that the vaccine could prevent EVD (RR 1.23, 95% CI 1.09-1.39), and reporting that religion influenced all decisions (RR 1.13, 95% CI 1.02-1.25). Ebola vaccine uptake was high in this population, although mixed attitudes and vaccine delays were common. Communicating positive vaccine information, emphasizing the efficacy of the Ebola vaccine, and engaging religious leaders to promote vaccination may aid in increasing Ebola vaccine uptake during future outbreaks.

Identifiers

PMID38236844
PMCPMC10796044
OpenAlexW4390970069

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.